Background {#Sec1}
==========

Over-distention of the normally aerated lung and/or opening and closing of collapsed alveoli may worsen pulmonary damage in patients with acute respiratory distress syndrome (ARDS). Current guidelines for ARDS recommend a protective ventilation strategy based on limitation of tidal volume (V~T~) to 6 mL/kg predicted body weight and plateau pressure (P~plat~) to 30 cmH~2~O, an approach that has been shown in a randomized clinical trial to reduce mortality by 9 % \[[@CR1]\]. However, recent studies have shown that ARDS patients who are ventilated according to the ARDS Network (ARDSnet) protective ventilatory strategy may still be exposed to forces that can induce lung injury \[[@CR2]--[@CR5]\], thus challenging current recommendations on how to minimize the risk of ventilator-induced lung injury (VILI) \[[@CR3]\]. Moreover, Hager and coworkers \[[@CR6]\] showed that mortality decreases as P~plat~ is reduced. However, as this relationship appears to be linear \[[@CR6]\], several authors have postulated that an ultra-protective ventilation strategy based on further reduction in V~T~ from 6--4 mL/kg and P~plat~ from 30--25 cmH~2~O may improve outcomes \[[@CR3]\]. Such tidal volumes reduce alveolar ventilation resulting in respiratory acidosis, which can be mitigated through the application of extracorporeal carbon dioxide removal (ECCO~2~R) \[[@CR7]--[@CR9]\].

The feasibility and safety of ultra-protective ventilation strategies facilitated by ECCO~2~R has been tested in several studies using a pump-less arteriovenous device operating at a blood flow rate of 1.0--1.5 L/min \[[@CR10]--[@CR12]\]. Information on feasibility and safety of ultra-protective ventilation strategies facilitated by low-flow venous-venous ECCO~2~R are limited to a single-center study \[[@CR8]\].

The aim of the current study was to assess in a multicenter trial the feasibility and safety of an ultra-protective ventilation strategy facilitated by low-flow veno-venous ECCO~2~R in patients with moderate ARDS. We used an ECCO~2~R system (Hemolung Respiratory Assist System, ALung Technologies), which is specifically designed to provide clinically significant CO~2~ removal at low blood flow rates (350--550 mL/min).

Methods {#Sec2}
=======

Patients were enrolled in four European intensive care units of academic hospitals. Local ethics committees approved the study protocol. Informed consent was obtained from the patients. In the case of incompetent patients, consent was obtained in accordance with local ethics committee procedures \[[@CR13]\].

Patients {#Sec3}
--------

The study included fifteen adult patients with moderate ARDS according to the Berlin definition (PaO~2~/FiO~2~ (P/F) 100--200 mmHg, with positive end-expiratory pressure (PEEP) \>5 cmH~2~O) \[[@CR14]\], who were mechanically ventilated with an expected duration of ventilation longer than 24 h. Exclusion criteria were age \<18 years, pregnancy, decompensated heart insufficiency or acute coronary syndrome, severe chronic obstructive pulmonary disease (COPD), respiratory acidosis with arterial PCO~2~ (PaCO2) \>80 mmHg, acute brain injury, severe liver insufficiency (Child-Pugh score \>7) or fulminant hepatic failure, heparin-induced thrombocytopenia, contraindication for systemic anticoagulation, patient moribund, decision to limit therapeutic interventions, catheter access to femoral vein or jugular vein impossible, pneumothorax, or platelet count \<50 × 10^3^/mL.

ECCO~2~R System {#Sec4}
---------------

Low-flow ECCO~2~R was provided with the Hemolung Respiratory Assist System (RAS) (ALung Technologies, Inc, Pittsburgh, PA, USA) \[[@CR15]\]. Briefly, venous blood is circulated through a 15.5-Fr dual lumen venous catheter (jugular or femoral) by a magnetically driven centrifugal pump at a flow rate of 350--550 mL/min. The pump is integrated within a cylindrical bundle of hollow fiber membranes, creating a flow pattern, which improves CO~2~ transfer efficiency relative to passive oxygenators. Sweep gas (air or 100 % O~2~) is drawn through the hollow fibers under negative pressure by a vacuum pump, creating a gradient for CO~2~ diffusion. Maintaining the sweep gas under negative pressure mitigates the risk of air embolism across the membrane, and also allows for automatic removal of plasmatic water condensation from the fiber lumens in order to preserve gas exchange efficiency. Level of blood flow, pump speed (RPM) and extracorporeal CO~2~ removal rate (vCO~2~) are displayed on a controller.

Study protocol {#Sec5}
--------------

Patients were sedated, paralyzed and ventilated in accordance with the EXPRESS trial protocol \[[@CR16]\]: V~T~ of 6 mL/kg (ideal body weight); PEEP set to achieve P~plat~ of 28--30 cmH~2~O; respiratory rate (RR) set to 20--35 to maintain approximately the same minute ventilation as before study initiation. Percutaneous venous femoral or jugular cannulation was performed through insertion of a single dual-lumen catheter (15.5 Fr) after administration of a heparin bolus (80 IU/kg). The device was activated at a blood flow rate of 350--550 mL/min and a sweep gas of 0 L/min such that no CO~2~ removal was initially performed.

Following a 2-h run-in time, V~T~ was gradually reduced from 6 to a minimum value of 4 mL/kg by 0.5 mL/kg every 30 minutes and PEEP was increased to target a P~plat~ between 23 and 25 cmH~2~O . If arterial pH was \<7.25 with PaCO~2~ \>60 mmHg, despite an increase in RR up to 35/min, sweep gas through the ECCO~2~R device was switched on with 100 % oxygen at 10 L/min to obtain an arterial pH ≥7.25 with a PaCO~2~ ≤60 mmHg and RR ≤35/min. If PaCO~2~ was \>75 mmHg and/or pH \<7.20, despite a respiratory rate of 35/min and optimized ECCO~2~R, sodium bicarbonate could be infused. If undesirable hypercapnia/acidosis persisted, V~[t]{.smallcaps}~ was increased at the discretion of the treating physician. Refractory hypoxemia and/or hypercapnia could be managed at the discretion of the attending physician using veno-venous extracorporeal membrane oxygenation (ECMO), prone positioning, or nitric oxide (NO) inhalation. If PaCO~2~ was constantly \<35 mmHg and/or pH was \>7.50 under the aforementioned ECCO~2~R settings, the respiratory rate was decreased to 18--22/min and sweep gas flow was decreased to 2--5 L/min.

The ECCO~2~R-facilitated ultra-protective ventilation strategy was continued for at least 24 h. The potential for weaning from ultra-protective ventilation and ECCO~2~R was assessed daily if PaO~2~/FiO~2~ (P/F) was \>200 by setting mechanical ventilation according to conventional ARDSnet settings (V~T~ = 6 mL/kg, PEEP 5--10 cmH~2~O, RR 20--30/min, inspired O~2~ fraction (FiO~2~) = 40 %) and switching off sweep gas through the ECCO~2~R device. Under these conditions, if the patient remained stable for at least 12 h with P~plat~ \<25 cmH~2~O and PaCO~2~ \<50 mmHg (allowing for RR up to 30--35/min), ECCO~2~R was discontinued and the venous catheter removed.

ECCO~2~R parameters (blood flow, sweep gas flow, and CO~2~ removal rate), ventilator settings (V~T~, PEEP, RR, P~plat~, mean airway pressure, minute ventilation, inspiratory-to-expiratory ratio, inspired fraction of oxygen), hemodynamics (mean arterial pressure, heart rate, dose of vasopressor) and arterial blood gas values (pH, PaO~2~, PaCO~2,~ HCO~3~ ^--^, lactate), heparin dose and activated partial thromboplastin time ratio (aPTTr) were collected at baseline, after run-in time, 30 minutes after every V~T~ reduction and at least twice a day (08:00 am ± 2 h and 08:00 pm ± 2 h) in the subsequent days on ECCO~2~R. Blood chemistry data were collected daily. Respiratory system compliance \[[@CR17]\] and driving pressure \[[@CR18]\] were calculated according to the standard formula.

Serious adverse events (SAE) were prospectively defined as: (a) any event that is fatal or immediately life threatening, permanently disabling, severely incapacitating or requires prolonged hospitalization; or (b) any event that may jeopardize the patient and requires medical or surgical intervention to prevent one of the outcomes listed above; and (c) which the attending physician perceives might be directly related to enrollment in the clinical trial. Adverse events were considered to be study-related if the event followed a reasonable sequence from a study procedure and could readily have been produced by the study procedure. Adverse events were considered non study-related if they were related primarily to the underlying disease or to ARDS and its sequelae. Other adverse events not fulfilling the above definition were recorded in the patients' case report forms (CRFs). Following discontinuation of ECCO~2~R, subjects were monitored for adverse events until hospital discharge or day 8 after enrollment, whichever occurred first.

Data are expressed as mean ± SD. Statistical analysis was performed by one-way analysis of variance for repeated measures, followed by Bonferroni post-hoc test for comparison between different time points (Stata Corp, College Station, TX, USA). *P* \<0.05 was considered statistically significant.

Results {#Sec6}
=======

Fifteen patients with moderate ARDS were included in the period April to November 2014. Baseline characteristics of patients enrolled in the study are shown in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of patientsVariablesPatients (n = 15)Age (years)55 ± 19Gender (male/female), number11/4Body mass index (kg/m^2^)24 ± 8Lung injury score (Murray)3 ± 0.9Risk factors for acute respiratory distress syndrome, number of patients Pulmonary  Pneumonia12 Non-pulmonary  Sepsis3Comorbidities, number of patients Diabetes mellitus3 Chronic obstructive pulmonary disease1 Arterial hypertension5 Coronary artery disease1 Chronic renal impairment2 Atrial fibrillation2 Alcohol use disorder4 Obesity2Simplified acute physiology score II51 ± 14Sequential organ failure assessment10 ± 4

Ventilation settings during the V~T~ reduction phase are shown in Table [2](#Tab2){ref-type="table"}. At baseline, all patients had PaO~2~/FiO~2~ ≤200, they were ventilated with a conventional protective ventilation strategy according to the EXPRESS trial protocol, and were paralyzed for a median time of 1 day kk. The initial stepwise reduction in V~T~, without ECCO~2~R, resulted in significant respiratory acidosis (pH \<7.25) in all 15 patients at a mean V~T~ of 3.96 ± 0.1 mL/kg. After initiation of ECCO~2~R, a V~T~ of 4.29 ± 0.5 mL/kg was achieved and respiratory acidosis was significantly corrected, with pH and PaCO~2~ returning to within 10 % of baseline values obtained at V~T~ = 6 mL/kg. The median number of days on ECCO~2~R was 3 (2--4). The reduction in V~T~ was associated with a significant reduction in P~plat~ from 27.7 ± 1.6 to 23.9 ± 1 cmH~2~O (*p* \<0.05) at day 1 and this difference remained significant throughout the study period (Table [3](#Tab3){ref-type="table"}). PEEP tended to increase from 12 ± 3 to 14 ± 2 cmH~2~O at day 1, however, this difference was not statistically significant over time (Table [3](#Tab3){ref-type="table"}). Driving pressure (P~plat~ -- PEEP) was significantly reduced during the first 2 days compared to baseline (*p* \<0.05); there were no significant differences in the values of respiratory system compliance (Fig. [1](#Fig1){ref-type="fig"}). At day 1, the ECCO~2~R device provided CO~2~ removal of 81 ± 9 mL/min at a blood flow rate of 435 ± 60 mL/min and sweep gas flow rate of 10 ± 0.3 L/min. The efficiency of the ECCO2R system was stable throughout the study period (Table [3](#Tab3){ref-type="table"}). Infusion of bicarbonate and renal replacement therapies for acute kidney injury were never used in this cohort of patients.Table 2Time course of ventilation variables during the run-in phaseVariablesBaselineV~T~ 5 mL/kgV~T~ 4.5 mL/kgV~T~ 4 mL/kgV~T~ (mL/kg)6.2 ± 0.75.02 ± 0.1\*4.48 ± 0.1\*3.96 ± 0.1\*Respiratory rate (beats/minute)28 ± 729 ± 430 ± 4\*30 ± 5\*Positive end-expiratory pressure (cmH~2~O)12 ± 313.8 ± 313.6 ± 413.0 ± 4.0Plateau pressure (cmH~2~O)27.7 ± 1.625.2 ± 1.6\*23.6 ± 1.3\*22.7 ± 1.8\*Patients who reached the pH threshold for ECCO~2~R, n0215\**P* \<0.05 vs baseline. *V* ~*T*~ tidal volume, *ECCO* ~*2*~ *R* extracorporeal carbon dioxide removal Table 3Time course of ventilation variables, blood gases, ECCO~2~R operational characteristics and hemodynamics at V~T~ 4 mL/kg plus ECCO~2~RVariablesBaselineV~T~ 4 mL/kg plus ECCO~2~RDay 1Day 2Day 3Time (h)8.008.008.0020.008.0020.00Patients (number)1515101086V~T~ (mL/kg)6.2 ± 0.74.29 ± 0.5\*4.58 ± 0.7\*4.59 ± 0.8\*4.8 ± 0.7\*4.8 ± 0.7\*Respiratory rate (beats/minute)28 ± 731.6 ± 4.6\*29.6 ± 6.829.6 ± 6.828 ± 727.4 ± 8.6Positive end-expiratory pressure (cmH~2~O)12 ± 314 ± 213 ± 312 ± 413 ± 513 ± 3Arterial partial pressure of oxygen/inspired oxygen fraction159 ± 34175 ± 45185 ± 91190 57176 ± 59176 ± 80Plateau pressure (cmH~2~O)27.7 ± 1.623.9 ± 1\*24 ± 4\*24 ± 3\*24 ± 3\*23 ± 3\*Blood flow (ml/min)435 ± 60424 ± 63423 ± 35424 ± 29436 ± 39Rotations per minute (RPM)1407 ± 261408 ± 301409 ± 321411 ± 361414 ± 41Sweep gas (L/min)8.6 ± 3.59.2 ± 2.99 ± 39.9 ± 0.38.7 ± 3.2CO~2~ removal (ml/min)81 ± 970 ± 2970 ± 3181 ± 2271 ± 11Ph7.36 ± 0.17.33 ± 0.17.39 ± 0.17.36 ± 0.17.33 ± 0.17.4 ± 0.1PaO2 (mmHg)95 ± 2990 ± 2291 ± 2684 ± 1081 ± 1599 ± 29PaCO2 (mmHg)51 ± 1553 ± 1551 ± 1852 ± 1755 ± 2049 ± 11HCO3 (mmol/L)28 ± 527.6 ± 6.128.7 ± 6.228. ± 6.928.1 ± 7.428.3 ± 6.03Lactate (mmol/L)2 ± 12.9 ± 4.81.9 ± 1.71.8 ± 1.81.9 ± 2.01.3 ± 0.4Heart rate (beats/minute)76 ± 990 ± 1786 ± 1595 ± 2194 ± 1994 ± 17Mean arterial pressure (mmHg)98 ± 2074 ± 1480 ± 1076 ± 1276 ± 1985 ± 14Norepinephrine dose (mcg/kg/min)0.51 ± 0.60.45 ± 0.40.34 ± 0.30.29 ± 0.270.57 ± 0.40.5 ± 0.6\**P* \<0.05 vs baseline. *V* ~*T*~ tidal volume, *ECCO* ~*2*~ *R* extracorporeal carbon dioxide removal Fig. 1Time course of respiratory system compliance (C~RS~) (**a**) and driving pressure (**b**). \**P* \<0.05 vs day 0. *Pts* patients

At day one, the heparin dosage was 341 ± 138 IU/kg/day with an aPTT ratio of 1.77 ± 0.7, and remained stable over time. The average baseline value of hemoglobin (Hb) was 10.4 ± 2 gr/dL, and the median Hb threshold for transfusion was 6.9 gr/dL (6.9--7.0). On day 1, four patients received 2.25 ± 0.5 red blood cell (RBC) units and 1.25 ± 2.5 pools of platelets. On day 2, only two patients received 1.5 ± 0.7 units of RBCs. On day 3, only one patient received two units of RBCs.

Two study-related adverse events were observed. In one patient, intravascular hemolysis (plasma-free hemoglobin 401.4 mg/dL) was observed resulting in a discontinuation of ECCO~2~R after 2 days. Kinking of the ECCO~2~R catheter caused a reduction in circuit blood flow in another patient. Individual data for patients who needed rescue therapies for worsening hypoxemia are given in Table [4](#Tab4){ref-type="table"}. The overall mortality at day 28 was 47 %. Among the eight survivors, six were successfully weaned from both ECCO~2~R and mechanical ventilation; while two patients were still dependent on ventilator support at 28 days.Table 4Oxygenation and outcomes of patients who required rescue therapiesPatientsTime of PaO~2~/FiO~2~ worseningPaO~2~/FiO~2~ before rescue therapyOutcome (at 28 days)(day)Prone positionECMO\# 15108Dead\# 5678Alive\# 8275Dead\# 112115Alive\# 121158Dead\# 131162Alive*PaO* ~*2*~ */FiO* ~*2*~ arterial partial pressure of oxygen/inspired oxygen fraction, *ECMO* extracorporeal membrane oxygenation

Discussion {#Sec7}
==========

The main finding of the current study is that the low-flow ECCO~2~R system effectively prevents respiratory acidosis consequent to the reduction of tidal volume to 4 mL/kg in patients with moderate ARDS. Severe hypoxemia occurred in about one third of the patients and was managed by prone positioning in conjunction with ECCO~2~R; conversion to VV-ECMO was required in two patients. Side effects related to ECCO~2~R (intravascular hemolysis and pump malfunction by femoral catheter kinking) were observed in two patients.

The landmark study by the ARDSnet demonstrated a 9 % mortality reduction in patients with ARDS by limiting plateau pressure to \<30 cmH~2~O \[[@CR1]\]. However, recent studies have shown that patients with ARDS may still be at risk of VILI despite values of P~plat~ ≤30 cmH~2~O \[[@CR2], [@CR4], [@CR5]\]. Terragni \[[@CR2]\] and Bellani \[[@CR4]\] showed that in some patients, tidal hyperinflation may still occur despite limiting V~T~ to 6 mL/kg and P~plat~ to 30 cmH~2~O, and that this is associated with biological signs of VILI, such as higher levels of inflammatory mediators and increased metabolic activity of the lungs. Grasso and coworkers showed that hyperinflation might be attenuated by reducing the levels of PEEP based on the shape of the airway pressure time curve and that this is associated with lower levels of pulmonary inflammatory cytokine release \[[@CR5]\]. Moreover, Hager and coworkers found that ARDS patients may benefit from V~T~ reduction even if they already have P~plat~ \<30 cmH~2~O \[[@CR6]\].

ECCO~2~R has been proposed to partially clear CO~2~ and consequently reduce the need of minute ventilation as delivered by conventional mechanical ventilation \[[@CR9]\]. The first evidence that ECCO~2~R might be a safe adjunctive therapy to conventional mechanical ventilation for ARDS patients dates back to the early 1980s \[[@CR19], [@CR20]\]. At that time, a modified veno-venous ECMO circuit with a blood flow not \>1 L/min allowed for dramatic reductions of minute ventilation and ventilator-applied pressure \[[@CR19]\]. More recently, Terragni and colleagues demonstrated that a modified renal replacement therapy circuit with an oxygenator in series with the hemofilter could facilitate an ultra-protective ventilation strategy, which may mitigate VILI \[[@CR8]\]. Our results extend these findings by performing a prospective multicenter study in 15 ARDS patients across four European ICUs.

Monitoring of respiratory mechanics may help clinicians in assessing the risk of VILI \[[@CR17]\]. In the presence of normal chest wall elastance, values of P~plat~ around 30 cmH~2~O may increase the risk of alveolar hyperinflation, which is the main determinant of VILI \[[@CR2]\]; analysis of a large dataset including ARDS patients previously enrolled in clinical trials, shows that driving pressure (i.e., the ratio of tidal volume to respiratory system compliance) is an independent risk factor for hospital mortality, because regardless of the changes in V~T~ and PEEP, only changes in driving pressure affected the outcome \[[@CR18]\]. Our data show that an ultra-protective ventilation strategy facilitated by low-flow veno-venous ECCO~2~R resulted in values of respiratory mechanics associated with enhanced protection from VILI as: (1) values of P~plat~ around 25 cmH~2~O, as achieved in this study, have been associated with lower serum levels of the pro-inflammatory cytokine interleukin-6 and a smaller percentage of lung hyperinflation, as demonstrated by computed tomography \[[@CR2], [@CR7], [@CR8]\]; and (2) our ultra-protective ventilation strategy resulted in a significant reduction in driving pressure. These findings allow us to speculate that in our patients, global interaction between moderate-to-high levels of PEEP and very low tidal volume, facilitated by ECCO~2~R, might be beneficial to minimize the risk of VILI.

In recent years, advances in technology have generated renewed interest in all extracorporeal support techniques. While high flow veno-venous ECMO has been increasingly used to treat life-threatening hypoxemia \[[@CR21], [@CR22]\], ECCO~2~R systems are used to provide partial-to-full CO~2~ removal with minimal effects on oxygenation \[[@CR9]\]. Appropriate strategies to manage worsening hypoxemia during ECCO~2~R treatment is a compelling issue. In fact, depending on the severity of lung injury, patients with ARDS may experience worsening of arterial oxygenation that might be life threatening \[[@CR23]\]. Moreover, the use of very low tidal volumes may expose patients to the risk of de-recruitment in the event that insufficient PEEP is applied. Consequently, prone positioning while the patient is still on ECCO~2~R, or shift to high-flow veno-venous ECMO, might be necessary. In this regard, prone positioning has been demonstrated to be effective not only in improving oxygenation but also in decreasing early and late mortality \[[@CR24]\]. In the current study, indication for rescue therapies for profound hypoxemia was not established by protocol. Within the first week of enrollment 27 % of patients in our cohort required prone positioning when their PaO2/FiO2 dropped to a median value of 137. Notably, patients underwent prone position without any interruption of ECCO~2~R and had improvement in arterial oxygenation. Only two patients required escalation from ECCO~2~R to ECMO because of life-threatening hypoxemia. Mortality at 28 days was 47 %, which was expected in a cohort of patients with moderate and severe ARDS.

Previous-generation ECCO~2~R systems have carried a high rate of mechanical complications such as pump malfunction, membrane clotting, and catheter displacement \[[@CR8]\]. In the current study, target blood flow rates were not reached in one case only due to a kinked catheter; otherwise, the treatment was consistent over time. Compared with arterio-venous systems in which limb ischemia, compartment syndrome, and intracranial hemorrhage have been described \[[@CR7]\], only one case of intravascular hemolysis requiring transfusion was reported in our series.

Some limitations of this study should be addressed. First, inferences from this study are limited by its small sample size. Second, although we speculate that the strategy tested in this multicenter study was lung-protective, we did not measure pro-inflammatory mediators associated with VILI and we did not evaluate lung volume/densities distribution with computed tomography of the chest. The precise impact of worsening oxygenation during ECCO~2~R treatment is also not clear. Consequently, this approach will be systematically tested in an upcoming randomized clinical trial, such as that under the auspices of European Society of Intensive Care Medicine, which will test the feasibility, safety and efficacy of several ECCO~2~R systems to facilitate ultra-protective ventilation - V~T~ of 4 mL/kg predicted body weight (PBW) and P~plat~ \<25 cmH~2~O - in patients with moderate and severe ARDS (SUPERNOVA: a strategy of ultraprotective lung ventilation with extracorporeal CO2 removal for new-onset moderate to severe ARDS) \[[@CR25]\].

Conclusions {#Sec8}
===========

In conclusion, low-flow ECCO~2~R is feasible, safe and efficient. It facilitates an ultra-protective mechanical ventilation strategy for reducing tidal volume to 4 mL/kg to maintain P~plat~ \<25 cmH~2~O. This approach allows the delivery of mechanical ventilation with relatively low driving airway pressures while preserving sufficient gas exchange and preventing hypercapnia and respiratory acidosis due to reduced ventilation. The current study provides a clinical and physiological rationale for testing whether ultra-protective mechanical ventilation improves clinical outcomes of patients with moderate and severe ARDS in randomized control trials.

Key messages {#Sec9}
============

Low-flow extracorporeal CO~2~ removal safely and effectively facilitates an ultra-protective ventilation strategy in patients with moderate ARDSThe current study provides a clinical and physiological rationale to study whether ultra-protective mechanical ventilation improves clinical outcomes of patients with moderate and severe ARDS in randomized control trials
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